Literature DB >> 24442761

Intralesional triamcinolone acetonide injection for the treatment of primary chalazions.

Michelle Y Y Wong1, Gordon S K Yau, Jacky W Y Lee, Can Y F Yuen.   

Abstract

The aim of this study was to investigate the safety and efficacy of intralesional triamcinolone acetonide (TA) injection in the treatment of primary chalazions not responding to conservative treatment. Patient medical records were retrospectively reviewed for all consecutive patients that received intralesional TA injection by a single surgeon between January 2012 and March 2013 for the treatment of unresolved primary chalazions despite 1 month of conservative treatment. The dose of TA injection ranged from 2 to 6 mg (40 mg/mL) depending on the size of the chalazion. The main outcome measures included time to resolution, time to 50 % size reduction, and complications from the treatment. During the study period, 48 chalazions from 38 patients were treated by intralesional TA injection. A 50 % reduction in size was achieved in 81.3 % of chalazions in 4 weeks and 83 % achieved complete resolution in 6 weeks. The mean time to complete resolution was 15.7 ± 10.0 days. There were no complications noted from the injections; 14.6 % required subsequent incision and curettage and 2.1 % required a second TA injection for complete resolution. Intralesional TA injection is a safe, simple, and effective procedure for the management of primary chalazions and may be considered as an alternative to incision and curettage in cases not responding to conservative treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24442761     DOI: 10.1007/s10792-014-9904-1

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  24 in total

1.  NOTES ON THREE CASES OF ACQUIRED ASTIGMATISM ASSOCIATED WITH MEIBOMIAN CYSTS.

Authors:  A W Ormond
Journal:  Br J Ophthalmol       Date:  1921-03       Impact factor: 4.638

2.  Laser chalazion removal.

Authors:  E L Korn
Journal:  Ophthalmic Surg       Date:  1988-06

3.  Three methods of treatment of chalazia in children.

Authors:  T A Mustafa; I H Oriafage
Journal:  Saudi Med J       Date:  2001-11       Impact factor: 1.484

4.  Subcutaneous steroid injection as treatment for chalazion: prospective case series.

Authors:  S Y Ho; J S M Lai
Journal:  Hong Kong Med J       Date:  2002-02       Impact factor: 2.227

5.  Intralesional triamcinolone acetonide injection for primary and recurrent chalazia: is it really effective?

Authors:  Guy J Ben Simon; Lynn Huang; Tanuj Nakra; Robert M Schwarcz; John D McCann; Robert A Goldberg
Journal:  Ophthalmology       Date:  2005-05       Impact factor: 12.079

6.  Intralesional corticosteroid therapy of chalazia.

Authors:  L D Pizzarello; F A Jakobiec; A J Hofeldt; M M Podolsky; D N Silvers
Journal:  Am J Ophthalmol       Date:  1978-06       Impact factor: 5.258

7.  Corticosteroid injection of chalazia.

Authors:  J Castrén; T Stenborg
Journal:  Acta Ophthalmol (Copenh)       Date:  1983-10

8.  Conservative treatment of chalazia.

Authors:  H D Perry; R A Serniuk
Journal:  Ophthalmology       Date:  1980-03       Impact factor: 12.079

9.  Ocular complication of intralesional corticosteroid injection of a chalazion.

Authors:  B M Hoşal; G Zilelioğlu
Journal:  Eur J Ophthalmol       Date:  2003 Nov-Dec       Impact factor: 2.597

10.  Retinal and choroidal vascular occlusion following intralesional corticosteroid injection of a chalazion.

Authors:  E L Thomas; R P Laborde
Journal:  Ophthalmology       Date:  1986-03       Impact factor: 12.079

View more
  2 in total

1.  Conservative therapy for chalazia: is it really effective?

Authors:  Albert Y Wu; Kalla A Gervasio; Kellie N Gergoudis; Chen Wei; James H Oestreicher; John T Harvey
Journal:  Acta Ophthalmol       Date:  2018-01-16       Impact factor: 3.761

2.  A prospective randomized study comparing incision and curettage with injection of triamcinolone acetonide for chronic chalazia.

Authors:  Reza Nabie; Hadi Soleimani; Leila Nikniaz; Shalaleh Raoufi; Elmira Hassanpour; Shokooh Mamaghani; Erfan Bahremani
Journal:  J Curr Ophthalmol       Date:  2019-05-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.